ÂÜÀòÂÒÂ×

Mr. Migausky has more than 30 years of public company leadership and senior financial management experience. He currently serves on the Board of Directors of Immunovant, Inc. Mr. Migausky previously served as interim Chief Financial Officer for Ocular Therapeutix, Inc. He also served as Executive Vice President and Chief Financial Officer of Dyax Corp., a position he held from 2008 through the company’s acquisition by the Shire in 2016. Earlier, he served as Chief Financial Officer of Wellstat Management Company and as Chief Financial Officer of IGEN International and BioVeris Corporation from 1986 through their acquisitions by F. Hoffman LaRoche in 2004 and 2007, respectively. Additionally, Mr. Migausky has served as a director at Hyperion Catalysis International since 2008 and as a trustee at the Massachusetts Eye and Ear Institute since 2015. He previously served as a director at Dimension Therapeutics, Inc. Mr. Migausky obtained a B.S. from Boston College and an M.B.A. in Finance from Babson College.